NCT04563845View on ClinicalTrials.gov

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

PHASE1CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

November 9, 2020

Primary Completion Date

October 30, 2021

Study Completion Date

October 30, 2021

Conditions

HIV Infections

Interventions

DRUG

GSK3640254

GSK3640254 will be administered.

DRUG

Placebo

Placebo will be administered.

DRUG

Moxifloxacin

Moxifloxacin will be administered.

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare

All Listed Sponsors

lead

ViiV Healthcare

INDUSTRY